✦ LIBER ✦

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

✍ Scribed by Banz, Kurt; Bischoff, Helge; Brunner, Matthias; Chouaid, Christos; de Castro Carpeño, Javier; de Marinis, Filippo; Grossi, Francesco; Vergnenègre, Alain; Walzer, Stefan

Book ID: 119320602
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 232 KB
Volume: 74
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2011.04.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN44 COST COMPARISON OF ERLOTINIB VERSU

PCN44 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN

✍ J Castro de Carpeño; AJ Castro-Gómez; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN43 COST COMPARISON OF ERLOTINIB VERSU

PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY

✍ S Ravera; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

A cross-market cost comparison of erloti

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer

✍ Nuijten, Mark J.C.; de Castro Carpeño, Javier; Chouaid, Christos; Vergnenègre, A 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 375 KB

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVER

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; K Banz; AJ Castro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PCN30 THE COSTS OF TREATING PATIENTS WIT

PCN30 THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY

✍ M Nuijten 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

PCN43 THE COST OF TREATING GRADE 3/4 ADV

PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

✍ C Chouaid; A Vergnenegre; M Brunner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB